Akorn ( AKRX) has announced that its Akorn-Strides joint venture has entered into a new agreement with Pfizer ( PFE) in which it will receive $35 million in cash for 16 abbreviated new drug approvals.

Shares of Akorn are up 1.1%, or 7 cents, to $6.46 in premarket trading.


Pfizer's animal health unit says it will acquire Synbiotics, a provider of laboratory diagnostic products for the animal health care industry. The acquisition is expected to close later this week.

Pfizer shares are up 0.28%, or 5 cents, to $17.65 in premarket trading.


Impax Laboratories ( IPXL) announced yesterday that the U.S. Food and Drug Administration has granted the company final approval for the generic version of Doryx, a drug used to treat bacterial infection, in 75 and 100 milligram tablets.

Shares of the company are up 0.15%, or 3 cents, to $20.54 in premarket trading.


-- Written by Theresa McCabe in Boston.

>To contact the writer of this article, click here: Theresa McCabe.

>To follow the writer on Twitter, go to @TheresaMcCabe.

>To submit a news tip, send an email to: tips@thestreet.com.

RELATED STORIES:










Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

China's Banks Halt Business With North Korea Per United Nations Sanctions

Why Hurricanes Won't Force the Fed to Ditch a December Rate Hike

Fed Pares $4.5 Trillion Balance Sheet But Easy-Money Era Isn't Over

Bank Stocks Move Higher as Fed Decides to Start Unwinding Balance Sheet

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'